CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 117 enrolled
Drug / intervention
Durvalumabdrug
Likely dose
Durvalumab 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03693300
NCT03693300Phase 2Completed
CompareCT.gov

A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)

AstraZeneca·interventional·Posted Oct 2, 2018·Updated Jun 18, 2024

In Brief

A Phase 2 clinical trial evaluating Durvalumab for Non-small Cell Lung Cancer (NSCLC). Completed, enrolled 117 participants across 28 sites in 6 countries.

Detailed Summary

This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) every 4 weeks \[q4w\] in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based sequential chemoradiation therapy (sCRT). This study will be conducted in Europe and North America.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer (NSCLC)
CountriesFrance, Germany, Italy, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2, 2018
Enrollment StartApr 16, 2019
Primary CompletionDec 13, 2022
Study CompletionApr 21, 2023
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.8 years ago

Interventions

Durvalumabdrug

Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.